GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

bezisterim   Click here for help

GtoPdb Ligand ID: 13988

Synonyms: 17-ethynyl-5-androstene-3,7,17-triol | HE-3286 | HE3286 | NE-3107 | NE3107
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Bezisterim (NE3107 and formerly HE3286) is a synthetic, orally bioavailable analogue of the adrenal sterol metabolite androstenetriol. It can cross the blood-brain barrier. It has proposed anti-inflammatory and insulin-sensitising activities, which may be beneficial in treating the pathophysiology or symptom development in degenerative brain diseases such as Parkinson's and Alzheimer's, which are associated with chronic low-grade inflammation. The molecular target(s) of bezisterim are not fully resolved. Its anti-inflammatory and insulin-sensitising biological activities likely include modulation of pathways and networks that involve LDL receptor related protein 1 (Lrp1), Mapk3 (ERK1) and Mapk1 (ERK2) [8].
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 3
Hydrogen bond donors 3
Rotatable bonds 0
Topological polar surface area 60.69
Molecular weight 330.46
XLogP 2.06
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES C#C[C@@]1(CC[C@H]2[C@H]3[C@H](CC[C@@]21C)[C@@]4(C)CC[C@@H](CC4=C[C@@H]3O)O)O
Isomeric SMILES C[C@]12CC[C@@H](CC1=C[C@@H]([C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@]4(C#C)O)C)O)O
InChI InChI=1S/C21H30O3/c1-4-21(24)10-7-16-18-15(6-9-20(16,21)3)19(2)8-5-14(22)11-13(19)12-17(18)23/h1,12,14-18,22-24H,5-11H2,2-3H3/t14-,15-,16-,17-,18+,19-,20-,21-/m0/s1
InChI Key JJKOQZHWYLMASZ-FJWDNACWSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
Bezisterim is a clinical candidate for the treatment of neurodegenerative diseases [4]. It is included as a drug intervention in the ADDRESS-LC long COVID clinical trial, which seeks to establish its effects on post-COVID-19 neurological symptoms.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT06757010 A Study of NE3107 in Early Parkinson's Phase 2 Interventional BioVie Inc. The ADDRESS-LC study
NCT06847191 NE3107 in Adults With Neurological Symptoms of Long COVID Phase 2 Interventional BioVie Inc.
NCT04669028 A Phase 3 Study of NE3107 in Probable Alzheimer's Disease Phase 3 Interventional BioVie Inc. 7,9